InspireMD (NSPR) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 10, 2020
Document And Entity Information
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	0001433607
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,338,910
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 3,141	$ 5,514
Accounts receivable:
Trade, net	856	823
Other	174	150
Prepaid expenses	63	87
Inventory	1,202	1,236
TOTAL CURRENT ASSETS	5,436	7,810
NON-CURRENT ASSETS:
Property, plant and equipment, net	496	547
Operating lease right of use assets	864	937
Fund in respect of employee rights upon retirement	589	586
TOTAL NON-CURRENT ASSETS	1,949	2,070
TOTAL ASSETS	7,385	9,880
Accounts payable and accruals:
Trade	562	646
Other	2,024	2,449
Contract liability	17	20
TOTAL CURRENT LIABILITIES	2,603	3,115
LONG-TERM LIABILITIES-
Operating lease liabilities	544	653
Liability for employees rights upon retirement	761	729
TOTAL LONG-TERM LIABILITIES	1,305	1,382
COMMITMENTS AND CONTINGENT LIABILITIES (Note 8)
TOTAL LIABILITIES	3,908	4,497
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at March 31, 2020 and December 31, 2019; 4,338,910 and 3,916,134 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
Additional paid-in capital	163,087	163,015
Accumulated deficit	(159,610)	(157,632)
Total equity	3,477	5,383
Total liabilities and equity	7,385	9,880
Series B Preferred Stock [Member]
EQUITY:
Preferred stock, value
Series C Preferred Stock [Member]
EQUITY:
Preferred stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	4,338,910	3,916,134
Common stock, shares outstanding	4,338,910	3,916,134
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	17,303	17,303
Preferred stock, shares outstanding	17,303	17,303
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares issued	26,558	34,370
Preferred stock, shares outstanding	26,558	34,370

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
REVENUES	$ 1,034	$ 415
COST OF REVENUES	739	488
GROSS PROFIT (LOSS)	295	(73)
OPERATING EXPENSES:
Research and development	523	1,125
Selling and marketing	624	634
General and administrative	1,169	1,298
Total operating expenses	2,316	3,057
LOSS FROM OPERATIONS	(2,021)	(3,130)
FINANCIAL EXPENSES (income), net	(43)	77
NET LOSS	$ (1,978)	$ (3,207)
NET LOSS PER SHARE - basic and diluted	$ (0.43)	$ (3.82)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic and diluted	4,623,034	839,533

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Common Stock [Member]		Series B Convertible Preferred Stock [Member]		Series C Convertible Preferred Stock [Member]		Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018		[1]		[1]		[1]	$ 156,355	$ (147,592)	$ 8,763
Balance, shares at Dec. 31, 2018	768,615		17,303		61,423
Net loss								(3,207)	(3,207)
Exercise of pre-funded warrants							16		16
Exercise of pre-funded warrants, shares	32,034
Conversion of Series C Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares, shares	854				(2,000)
Share-based compensation related to restricted stock and stock options award, net of forfeitures of shares							68		68
Share-based compensation related to restricted stock and stock options award, net of forfeitures of shares, shares	70,369
Balance at Mar. 31, 2019							156,439	(150,799)	5,640
Balance, shares at Mar. 31, 2019	871,872		17,303		59,423
Balance at Dec. 31, 2019		[1]		[1]		[1]	163,015	(157,632)	5,383
Balance, shares at Dec. 31, 2019	3,916,134		17,303		34,370
Net loss								(1,978)	(1,978)
Exercise of pre-funded warrants							$ 3		$ 3
Exercise of pre-funded warrants, shares	270,000
Conversion of Series C Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares, shares	27,776				(7,812)
Share-based compensation related to restricted stock and stock options award, net of forfeitures of shares							$ 69		$ 69
Share-based compensation related to restricted stock and stock options award, net of forfeitures of shares, shares	(40,000)
Settlement of restricted stock units in shares of common stock
Settlement of restricted stock units in shares of common stock, shares	165,000
Balance at Mar. 31, 2020							$ 163,087	$ (159,610)	$ 3,477
Balance, shares at Mar. 31, 2020	4,338,910		17,303		26,558
[1]	Represents an amount less than $1 thousand

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Restricted stock award, shares	40,000	212

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,978)	$ (3,207)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	51	35
Change in liability for employees rights upon retirement	32	37
Financial income and interest paid	19	5
Lease liability	(31)	34
Share-based compensation expenses	69	68
Loss on amounts funded in respect of employee rights upon retirement, net		5
Changes in operating asset and liability items:
Decrease in prepaid expenses	24	15
Decrease (Increase) in trade receivables	(33)	252
Increase in other receivables	(24)	(82)
Decrease (Increase) in inventory	34	(313)
(Decrease) increase in trade payables	(84)	(57)
(Decrease) increase in other payables and contract liability	(433)	(277)
Net cash used in operating activities	(2,354)	(3,485)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment		(66)
Amounts (withdrawn) in respect of employee rights upon retirement, net	(3)	(39)
Net cash used in investing activities	(3)	(105)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of Pre-Funded Warrants	3	16
Net cash provided by financing activities	3	16
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(19)	(3)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(2,373)	(3,577)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	5,514	9,384
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	3,141	5,807
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES:
Issuance Costs		$ 49

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company’s coronary product combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company markets its products through distributors in international markets, mainly in Europe. b. Liquidity The Company has an accumulated deficit as of March 31, 2020, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its products (primarily CGuard™ EPS) reach commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company has sufficient resources to fund operations until the end of August 2020. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. The COVID-19 pandemic has resulted in significant financial market volatility and uncertainty in recent weeks. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital and on the market price of our common stock, and we may not be able to successfully raise capital through the sale of our securities. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations. c. COVID-19 Pandemic During the three months ended March 31, 2020, in an effort to contain and mitigate the spread of a strain of coronavirus, COVID-19, many countries have imposed unprecedented restrictions on travel, quarantines and other public health safety measures. Procedures with CGuard EPS, which are generally scheduled or non-emergency procedures, have mostly been postponed as hospitals shift resources to patients affected by COVID-19, and we do not know when the hospitals will resume to normal pre-pandemic levels with such procedures. In addition, most of our sales have historically come from Europe, where the pandemic has had a severe impact. At this point, the extent to which COVID-19 may impact our business cannot be estimated; however, we anticipate that the continuation of the pandemic and related restrictions and safety measures may result in a significant decline in sales of our products for the upcoming periods. In response to the significant market volatility and uncertainties relating to COVID-19, the Company board of directors, management and most of the employees have taken reductions of compensation as a measure of fiscal responsibility.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 2 - BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position and results of operations of the Company. These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2019, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 10, 2020. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of results that could be expected for the entire fiscal year.

Equity

Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Equity	NOTE 3 - EQUITY: a. During the three months ended March 31, 2020, the Company issued a total of 270,000 shares of its common stock in connection with the exercise of 270,000 Pre-Funded Warrants issued in September 2019. As of March 31, 2020, there are no outstanding Pre-Funded Warrants. b. During the three months ended March 31, 2020, 7,812 shares of Series C Convertible Preferred Stock were converted into 27,776 shares of common stock. c. As of March 31, 2020, the number of preferred shares and the amount each class is convertible into is below: Number of Number of Series B Convertible Preferred Stock 17,303 555,138 * Series C Convertible Preferred Stock 26,558 94,428 Total 649,566 * Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any. As of March 31, 2020, the Company has outstanding warrants to purchase an aggregate of 4,016,597 shares of common stock as follows: Number of Weighted Series A Warrants 1,102 $ 8,750.00 Series B Warrants 2,448 $ 3,500.00 Series D Warrants 806,698 $ 15.19 Series E Warrants 2,972,221 $ 1.80 April 2019 Underwriter Warrants 34,955 $ 6.25 September 2019 Underwriter Warrants 194,444 $ 2.25 Other warrants 4,729 $ 587 Total Warrants 4,016,597 $ 9.77 As of March 31, 2020, the Company had 155,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock. In connection with an Employment Agreement with a new chief executive officer and president, the Company granted 182,381 restricted stock units and stock options to purchase 60,794 shares of common stock at $1.10 per share. The restricted stock units and options are subject to a three-year vesting period, with one-third of such awards vesting each year. The fair value of the restricted stock units was approximately $0.2 million.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	NOTE 4- NET LOSS PER SHARE: Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options, warrants, and restricted stocks as the effect is anti-dilutive. The total number of shares of common stock related to outstanding options, warrants, restricted stock, restricted stock units, Series C Preferred Stock and placement agent units excluded from the calculations of diluted loss per share were 4,437,453 for the three-month period ended March 31, 2020. The total number of shares of common stock related to outstanding options, warrants, restricted stock, Series C Preferred Stock and placement agent units excluded from the calculations of diluted loss per share were 913,320 for three-month period ended March 31, 2019.

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 5 - FAIR VALUE MEASURMENT: Fair value of financial instruments The carrying amounts of financial instruments included in working capital approximate their fair value either because these amounts are presented at fair value or due to the relatively short-term maturities of such instruments. As of March 31, 2020, and December 31, 2019, allowance for doubtful accounts was $0.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory	NOTE 6 - INVENTORY: March 31, December 31, 2020 2019 ($ in thousands) Finished goods $ 33 $ 173 Work in process 281 81 Raw materials and supplies 888 982 $ 1,202 $ 1,236

Accounts Payable and Accruals -

Accounts Payable and Accruals - Other	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accruals - Other	NOTE 7 - ACCOUNTS PAYABLE AND ACCRUALS - OTHER: March 31, December 31, 2020 2019 ($ in thousands) Employees and employee institutions 729 1,238 Accrued vacation and recreation pay 209 188 Accrued expenses 660 604 Provision for sales commissions 15 - Current Operating lease liabilities 367 362 Other 44 57 $ 2,024 $ 2,449

Commitments and Contingent Liab

Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 8 - COMMITMENTS AND CONTINGENT LIABILITIES: a. Lease Agreements 1) The Company’s Israeli subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2020 with an option to extend the agreement for two additional years until December 31, 2022 under the terms stipulated in the agreement (the Option Period). The Option Period was taken in consideration when calculating the operating lease right of use assets and liabilities since it is reasonably certain that the company will exercise the option. 2) The Company leases its motor vehicles under operating lease agreements. b. Litigation: In July 2019, a former distributor filed a suit seeking damages from the Company’s subsidiary for pre-paid goods subject to the voluntary field action (from April 2014) amounting to €1,830,000 (which is approximately $2.0 million), or alternatively €1,024,000 (which is approximately $1.1 million). After considering the views of its legal counsel as well as other factors, the Company’s management believes that there is a reasonably possible likelihood of a loss from any related future proceedings would range from a minimal amount up to €1,830,000.

Disaggregated Revenue and Entit

Disaggregated Revenue and Entity Wide Disclosures	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Disaggregated Revenue and Entity Wide Disclosures	NOTE 9 - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Three months ended 2020 2019 ($ in thousands) Italy $ 194 $ 80 Germany 171 128 Poland 121 - Russia 116 - Other 432 207 $ 1,034 $ 415 By product: Three months ended 2020 2019 ($ in thousands) CGuard $ 971 $ 376 MGuard 63 39 $ 1,034 $ 415 By principal customers: Three months ended 2020 2019 Customer A 16 % 29 % Customer B 16 % 6 % Customer C 12 % - Customer D 11 % - Customer E 3 % 13 % All tangible long lived assets are located in Israel.

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Convertible Preferred Shares	As of March 31, 2020, the number of preferred shares and the amount each class is convertible into is below: Number of Number of Series B Convertible Preferred Stock 17,303 555,138 * Series C Convertible Preferred Stock 26,558 94,428 Total 649,566 * Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any.
Schedule of Issuance of Warrants to Purchase Common Stock	As of March 31, 2020, the Company has outstanding warrants to purchase an aggregate of 4,016,597 shares of common stock as follows: Number of Weighted Series A Warrants 1,102 $ 8,750.00 Series B Warrants 2,448 $ 3,500.00 Series D Warrants 806,698 $ 15.19 Series E Warrants 2,972,221 $ 1.80 April 2019 Underwriter Warrants 34,955 $ 6.25 September 2019 Underwriter Warrants 194,444 $ 2.25 Other warrants 4,729 $ 587 Total Warrants 4,016,597 $ 9.77

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	March 31, December 31, 2020 2019 ($ in thousands) Finished goods $ 33 $ 173 Work in process 281 81 Raw materials and supplies 888 982 $ 1,202 $ 1,236

Accounts Payable and Accruals_2

Accounts Payable and Accruals - Other (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accruals - Other	March 31, December 31, 2020 2019 ($ in thousands) Employees and employee institutions 729 1,238 Accrued vacation and recreation pay 209 188 Accrued expenses 660 604 Provision for sales commissions 15 - Current Operating lease liabilities 367 362 Other 44 57 $ 2,024 $ 2,449

Disaggregated Revenue and Ent_2

Disaggregated Revenue and Entity Wide Disclosures (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Schedule of Revenues Attributed to Geographic Areas	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Three months ended 2020 2019 ($ in thousands) Italy $ 194 $ 80 Germany 171 128 Poland 121 - Russia 116 - Other 432 207 $ 1,034 $ 415
Schedule of Revenues Attributed to Geographic Areas by Product	By product: Three months ended 2020 2019 ($ in thousands) CGuard $ 971 $ 376 MGuard 63 39 $ 1,034 $ 415
Schedule of Revenues Attributed to Geographic Areas by Principal Customers	By principal customers: Three months ended 2020 2019 Customer A 16 % 29 % Customer B 16 % 6 % Customer C 12 % - Customer D 11 % - Customer E 3 % 13 %

Equity (Details Narrative)

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
Pre-funded warrants, shares			270,000
Outstanding pre-funded warrants are exercisable into shares of common stock
Convertible preferred stock shares issued upon conversion	649,566
Number of warrants to purchase common stock	4,016,597
Capital stock shares authorized	155,000,000
Capital stock par value	$ 0.0001
Common stock shares authorized	150,000,000	150,000,000
Fair value of restricted stock units	$ 200
Restricted Stock [Member] | New Chief Executive Officer and President [Member]
Stock option granted	182,381
Stock options to purchase a share of common stock	60,794
Share issued price per shares	$ 1.10
Stock option vesting period	3 years
Series C Convertible Preferred Stock One [Member]
Convertible preferred stock shares issued upon conversion	7,812
Common Stock [Member]
Number of common stock shares issued	270,000
Convertible preferred stock shares issued upon conversion	27,776
Preferred Stock Blank Check [Member]
Preferred stock shares authorized	5,000,000

Equity - Schedule of Convertibl

Equity - Schedule of Convertible Preferred Shares (Details)	3 Months Ended
	Mar. 31, 2020shares
Class of Stock [Line Items]
Number of underlying Common Stock	649,566
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of Preferred Stock	17,303
Number of underlying Common Stock	555,138	[1]
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of Preferred Stock	26,558
Number of underlying Common Stock	94,428
[1]	Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company's discretion, but excluding effect of future conversion price adjustment, if any.

Equity - Schedule of Converti_2

Equity - Schedule of Convertible Preferred Shares (Details) (Parenthetical)	3 Months Ended
	Mar. 31, 2020
Series B Convertible Preferred Stock [Member]
Cumulative dividend rate	15.00%

Equity - Schedule of Issuance o

Equity - Schedule of Issuance of Warrants to Purchase Common Stock (Details)	Mar. 31, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Total Warrants | shares	4,016,597
Weighted average exercise price | $ / shares	$ 9.77
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	1,102
Weighted average exercise price | $ / shares	$ 8,750
Series B Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	2,448
Weighted average exercise price | $ / shares	$ 3,500
Series D Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	806,698
Weighted average exercise price | $ / shares	$ 15.19
Series E Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	2,972,221
Weighted average exercise price | $ / shares	$ 1.80
April 2019 Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	34,955
Weighted average exercise price | $ / shares	$ 6.25
September 2019 Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	194,444
Weighted average exercise price | $ / shares	$ 2.25
Other Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	4,729
Weighted average exercise price | $ / shares	$ 587

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Number of antidilutive securities excluded from computation of earnings per share	4,437,453	913,320

Fair Value Measurement (Details

Fair Value Measurement (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Allowance for doubtful accounts	$ 0	$ 0

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 33	$ 173
Work in process	281	81
Raw materials and supplies	888	982
Total inventory	$ 1,202	$ 1,236

Accounts Payable and Accruals_3

Accounts Payable and Accruals - Other - Schedule of Accounts Payable and Accruals - Other (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Employees and employee institutions	$ 729	$ 1,238
Accrued vacation and recreation pay	209	188
Accrued expenses	660	604
Provision for sales commissions	15
Current Operating lease liabilities	367	362
Other	44	57
Accounts Payable and Accruals - Other	$ 2,024	$ 2,449

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details Narrative) € in Thousands, $ in Thousands	1 Months Ended		3 Months Ended
	Jul. 31, 2019USD ($)	Jul. 31, 2019EUR (€)	Mar. 31, 2020
Lease expiration date			Dec. 31, 2020
Lease, description			The Company's Israeli subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2020 with an option to extend the agreement for two additional years until December 31, 2022 under the terms stipulated in the agreement (the Option Period).
Former Distributor [Member]
Law suit seeking damages	$ 2,000
Law suit seeking damages, description	In July 2019, a former distributor filed a suit seeking damages from the Company's subsidiary for pre-paid goods subject to the voluntary field action (from April 2014) amounting to €1,830,000 (which is approximately $2.0 million), or alternatively €1,024,000 (which is approximately $1.1 million).	In July 2019, a former distributor filed a suit seeking damages from the Company's subsidiary for pre-paid goods subject to the voluntary field action (from April 2014) amounting to €1,830,000 (which is approximately $2.0 million), or alternatively €1,024,000 (which is approximately $1.1 million).
Former Distributor [Member] | Alternatively [Member]
Law suit seeking damages	$ 1,100
Former Distributor [Member] | Euro [Member]
Law suit seeking damages | €		€ 1,830
Claim range amount up to	$ 1,830
Former Distributor [Member] | Euro [Member] | Alternatively [Member]
Law suit seeking damages | €		€ 1,024

Disaggregated Revenue and Ent_3

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues	$ 1,034	$ 415
Italy [Member]
Revenues	194	80
Germany [Member]
Revenues	171	128
Poland [Member]
Revenues	121
Russia [Member]
Revenues	116
Other [Member]
Revenues	$ 432	$ 207

Disaggregated Revenue and Ent_4

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas by Product (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 1,034	$ 415
CGuard [Member]
Segment Reporting Information [Line Items]
Revenue	971	376
MGuard [Member]
Segment Reporting Information [Line Items]
Revenue	$ 63	$ 39

Disaggregated Revenue and Ent_5

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas by Principal Customers (Details) - Sales [Member]	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Customer A [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	16.00%	29.00%
Customer B [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	16.00%	6.00%
Customer C [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	12.00%
Customer D [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	11.00%
Customer E [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	3.00%	13.00%